Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IITreatmentCompletedNot specifiedNCI, OtherRTOG-9904
CDR0000067026, RTOG-DEV-1046, NCT00003862

Trial Description


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of chemotherapy and radiation therapy in treating patients who have stomach cancer.

Further Study Information


  • Determine the feasibility of preoperative chemoradiotherapy in patients with potentially resectable adenocarcinoma of the stomach.
  • Determine the pathologic response rate, curative resection rate, and survival in patients treated with this regimen.
  • Determine the tolerability of this regimen in these patients.

OUTLINE: Patients receive fluorouracil IV over 24 hours on days 1-21, cisplatin IV over 1 hour on days 1-5, and leucovorin calcium IV over 15 minutes on days 1, 8, 15, and 22. A second course is administered beginning on day 29.

Chemoradiotherapy begins at the end of the second course of chemotherapy and 1 week of rest (day 57). Patients receive fluorouracil IV over 24 hours 5 days a week concurrently with radiotherapy for 5 weeks and paclitaxel IV over 3 hours once weekly during these 5 weeks on days 1, 8, 15, 22, and 29.

Approximately 4-5 weeks after chemoradiotherapy, patients with no evidence of metastatic disease undergo surgical resection.

Patients are followed every 3 months for 1 year, every 6 months for 5 years, then annually thereafter.

PROJECTED ACCRUAL: A total of 21-49 patients will be accrued for this study within 2.5 years.

Eligibility Criteria


  • Histologically proven adenocarcinoma of the stomach
  • Stage IB, II, IIIA, IIIB, and IV (T2-3, any N, M0)
  • No lymph node metastases outside the field of resection (e.g., supraclavicular, mediastinal, or paraaortic nodes)
  • Potentially resectable
  • May involve the gastroesophageal junction, but bulk of tumor must be in the stomach
  • No distant metastases
  • No pleural or pericardial effusion
  • No peritoneal disease diagnosed by laparoscopy



  • Not specified

Performance status:

  • Zubrod 0-2

Life expectancy:

  • At least 16 weeks


  • Absolute granulocyte count greater than 2,000/mm^3
  • Platelet count greater than 100,000/mm^3


  • Bilirubin no greater than 1.5 mg/dL


  • Creatinine less than 1.5 mg/dL


  • No New York Heart Association class III or IV heart disease
  • No hypertension


  • No cerebrovascular disease
  • No diabetic neuropathy
  • No mental status abnormalities


  • No uncontrolled diabetes
  • No infection
  • No other malignancies within past 5 years except resected squamous cell or basal cell skin cancer
  • Not pregnant or nursing
  • Fertile patients must use effective contraception


Biologic therapy:

  • No prior immunotherapy


  • No prior chemotherapy

Endocrine therapy:

  • Not specified


  • No prior radiotherapy to stomach


  • No prior surgery to stomach

Trial Contact Information

Trial Lead Organizations/Sponsors

Radiation Therapy Oncology Group

  • National Cancer Institute
Jaffer A. Ajani, Study Chair

Link to the current record.
NLM Identifier NCT00003862 processed this data on April 09, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to